215 related articles for article (PubMed ID: 38390025)
1. Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure.
Amin AN; Kartashov A; Ngai W; Steele K; Rosenthal N
J Health Econ Outcomes Res; 2024; 11(1):44-56. PubMed ID: 38390025
[No Abstract] [Full Text] [Related]
2. Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity.
Amin A; Kartashov A; Ngai W; Steele K; Rosenthal N
Front Cardiovasc Med; 2023; 10():1163684. PubMed ID: 37396589
[TBL] [Abstract][Full Text] [Related]
3. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
Veeranki SP; Xiao Z; Levorsen A; Sinha M; Shah BR
Am J Cardiovasc Drugs; 2021 Jul; 21(4):443-452. PubMed ID: 33313988
[TBL] [Abstract][Full Text] [Related]
4. A Real-World Comparative Effectiveness Analysis of Thromboprophylactic Use of Enoxaparin Versus Unfractionated Heparin in Abdominal Surgery Patients in a Large U.S. Hospital Database.
Veeranki SP; Xiao Z; Levorsen A; Sinha M; Shah B
Hosp Pharm; 2022 Feb; 57(1):121-129. PubMed ID: 35521006
[No Abstract] [Full Text] [Related]
5. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients.
McGarry LJ; Stokes ME; Thompson D
Thromb J; 2006 Sep; 4():17. PubMed ID: 17005045
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
Amin AN; Lin J; Lenhart G; Schulman KL
Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
[TBL] [Abstract][Full Text] [Related]
7. Cost reduction associated with heparin-induced thrombocytopenia panel ordering for enoxaparin versus heparin for prophylactic and therapeutic use: A retrospective analysis in a community hospital setting.
Menon H; Pillai A; Aussenberg-Rodriguez J; Ambrose J; Youssef I; Griffiths EA; Al Ustwani O
Avicenna J Med; 2018; 8(4):133-138. PubMed ID: 30319954
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
[TBL] [Abstract][Full Text] [Related]
9. Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.
Changolkar A; Menditto L; Shah M; Puto K; Farrelly E
Am J Health Syst Pharm; 2014 Apr; 71(7):562-9. PubMed ID: 24644116
[TBL] [Abstract][Full Text] [Related]
10. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
Argenta C; Ferreira MA; Sander GB; Moreira LB
Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Deitelzweig SB; Becker R; Lin J; Benner J
Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
[TBL] [Abstract][Full Text] [Related]
14. Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.
Busani S; Tosi M; Mighali P; Vandelli P; D'Amico R; Marietta M; Forfori F; Donati A; Cinnella G; De Monte A; Pasero D; Bellani G; Tascini C; Foti G; Ranieri M; Girardis M
Trials; 2020 Aug; 21(1):724. PubMed ID: 32807241
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome.
Rosenthal N; Xiao Z; Kartashov A; Levorsen A; Shah BR
Am J Cardiovasc Drugs; 2021 Jan; 21(1):93-101. PubMed ID: 32578166
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Hemodialysis Patients.
Green MS; Tellor KB; Buckallew AR
Hosp Pharm; 2017 Oct; 52(9):623-627. PubMed ID: 29276299
[No Abstract] [Full Text] [Related]
17. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice.
McGarry LJ; Thompson D
Clin Ther; 2004 Mar; 26(3):419-30. PubMed ID: 15110135
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
DeBiase C; Giuliano CA; Doshi M; Ganoff M; Alexander Paxton R
Pharmacotherapy; 2021 May; 41(5):424-429. PubMed ID: 33641194
[TBL] [Abstract][Full Text] [Related]
19. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
Dunn CJ; Goa KL
Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.
Bain E; Wilson A; Tooher R; Gates S; Davis LJ; Middleton P
Cochrane Database Syst Rev; 2014 Feb; (2):CD001689. PubMed ID: 24519568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]